Piramal Critical Care announces US launch of Chlorpromazine Hydrochloride for Injection
The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care
The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
According to IQVIATM sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
This is the second Ready-To-Use Infusion bag (RTU Bags) ANDA drug product approved for Caplin Steriles
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets
Subscribe To Our Newsletter & Stay Updated